The Ibogaine Dossier
The Ibogaine Dossier

Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback
The Ibogaine Dossier

Previous abstract | Next abstract


Ibogaine neurotoxicity: a re-evaluation. Molinari, H.H., Maisonneuve, I.M. and Glick, S.D. Brain Res 737:255-262, 1996.

Abstract: Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 x 100 mg/kg) and sought to determine when a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with a high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobes 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contract, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and anti-addictive properties of ibogaine reflect different actions of the drug.


Previous abstract | Next abstract



Top of page | Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback

Tabernanthe iboga © 1997
The Ibogaine Dossier